Log in to save to my catalogue

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical tri...

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical tri...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11032558

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease

About this item

Full title

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease

Publisher

United States: John Wiley & Sons, Inc

Journal title

Alzheimer's & dementia, 2024-04, Vol.20 (4), p.2698-2706

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

INTRODUCTION
Increasing evidence suggests that amyloid reduction could serve as a plausible surrogate endpoint for clinical and cognitive efficacy. The double‐blind phase 3 DIAN‐TU‐001 trial tested clinical and cognitive declines with increasing doses of solanezumab or gantenerumab.
METHODS
We used latent class (LC) analysis on data from t...

Alternative Titles

Full title

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11032558

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11032558

Other Identifiers

ISSN

1552-5260,1552-5279

E-ISSN

1552-5279

DOI

10.1002/alz.13735

How to access this item